Encrypted login | home

Program Information

Multi-Helix Rotating Shield Brachytherapy for Cervical Cancer


H Dadkhah

H Dadkhah1*, R Flynn2 , X Wu1 , Y Kim2 , (1) University of Iowa, Iowa City, IA, (2) University of Iowa Hospitals and Clinics, Iowa City, IA

Presentations

SU-E-T-564 (Sunday, July 12, 2015) 3:00 PM - 6:00 PM Room: Exhibit Hall


Purpose:
To present a novel and practical brachytherapy technique, called multi-helix rotating shield brachytherapy (H-RSBT), for the precise positioning of a partial shield in a curved applicator. H-RSBT enables RSBT delivery using only translational motion of the radiation source/shield combination. H-RSBT overcomes the challenges associated with previously proposed RSBT approaches based on a serial (S-RSBT) step-and-shoot delivery technique, which required independent translational and rotational motion.

Methods:
A Fletcher-type applicator, compatible with the combination of a Xoft Axxent™ electronic brachytherapy source and a 0.5 mm thick tungsten shield, is proposed. The wall of the applicator contains six evenly-spaced helical keyways that rigidly define the emission direction of the shield as a function of depth. The shield contains three protruding keys and is attached to the source such that it rotates freely. S-RSBT and H-RSBT treatment plans with 180° and 45° azimuthal emission angles were generated for five cervical cancer patients representative of a wide range of high-risk clinical target volume (HR-CTV) shapes and applicator positions. The number of beamlets used in the treatment planning process was nearly constant for S-RSBT and H-RSBT by using dwell positions separated by 5 and 1.7 mm, respectively, and emission directions separated by 22.5° and 60°, respectively. For all the treatment plans the EQD2 of the HR-CTV was escalated until the EQD2 D2cc tolerance of either the bladder, rectum, or sigmoid colon was reached.

Results:
Treatment times for H-RSBT tended to be shorter than for S-RSBT, with changes of -38.47% to 1.12% with an average of -8.34%. The HR-CTV D₉₀ changed by -8.81% to 2.08% with an average of -2.46%.

Conclusion:
H-RSBT is a mechanically feasible technique in the curved applicators needed for cervical cancer brachytherapy. S-RSBT and H-RSBT dose distributions were clinically equivalent for all patients considered, with the H-RSBT deliveries tending to be faster.

Funding Support, Disclosures, and Conflict of Interest: Ryan Flynn has ownership interest in pxAlpha, LLC, which is a startup company developing a rotating shield brachytherapy system.


Contact Email: